Immtech Pharmaceuticals has enlisted Jubo Liu, PhD, to serve as Development Liaison for Clinical Trials in China. Currently, Immtech is conducting a Phase III trial of pafuramidine as a treatment for pneumocystis pneumonia (PCP), a fungal infections affecting patients with compromised immune systems. This includes people with HIV/AIDS and transplant patients. An estimated 1 million people worldwide suffer from the disease, while another 5 million people are treated prophylactically for the disease. The China State Food & Drug Administration recently granted Fast Track Status to the Phase III trial of pafuramidine. More details...

Stock Symbols: (AMEX: IMM) (NYSE: PRX) (NSDQ: VRTX)